Table 1.
Clinical characteristics of cohorts studied
| Cohort | Total | Development (SuMR) | Validation (SCOTRRCC) |
|---|---|---|---|
| Number of patients | 44 | 22 | 22 |
| Age, median (range)a | 66.5 (38.2–79.3) | 64.5 (44–78) | 67.5 (38.2–79.3) |
| Overall survival (months):b | |||
| Median | 16.2 | 23.5 | 12.3 |
| Interquartile range | 9.1–25.9 | 14.8–29.8 | 7.6–18.8 |
| Number censored | 22 | 10 | 12 |
| Modes (bimodal model) | 10.6, 27.3 | 10.2, 27.4 | 11.6, 27.5 |
| Number of samples per tumoura median (range) | 4 (1–10) | 4 (1–10) | 4 (2–8) |
| Male genderb | 29 | 15 | 14 |
| Fuhrman grade:b | |||
| 4 | 9 | 1 | 8 |
| 3 | 22 | 12 | 10 |
| 2 | 13 | 9 | 4 |
| Stage:b | |||
| T4 | 4 | 4 | 0 |
| T3 | 33 | 13 | 20 |
| T2 | 6 | 4 | 2 |
| T1 | 1 | 1 | 0 |
| Performance status:c | |||
| KPS >80 (unavailable) | 34 (1) | 13 (0) | 21 (1) |
| Anaemiab ,+ (unavailable) | 22 (2) | 12 (0) | 10 (2) |
| Raised calciumb (unavailable) | 8 (7) | 5 (0) | 3 (7) |
| Raised LDHc (unavailable) | 10 (15) | 5 (0) | 5 (15) |
| Neutrophil count >70% upper limit of normalb (unavailable) | 9 (2) | 2 (0) | 7 (2) |
| Platelet count >400b (unavailable) | 12 (2) | 6 (0) | 6 (2) |
| VHL mutationb | 31 | 14 | 17 |
| Renal response at surgery: | |||
| Partial response | – | 2 | – |
| Stable disease | – | 20 | – |
| Number of metastatic sites:b | |||
| 1 | 19 | 6 | 13 |
| 2 | 18 | 11 | 7 |
| 3 | 7 | 5 | 2 |
| IMDC class:b | |||
| Intermediate | 26 | 12 | 14 |
| Poor | 16 | 10 | 6 |
| Unavailable | 2 | 0 | 2 |
| MSKCC class:b | |||
| Favourable/intermediate: | 26 | 13 | 13 |
| Poor | 12 | 9 | 3 |
| Unavailable | 6 | 0 | 6 |
+Hb <130 (M), <110 (F); a p < 0.05; b p > 0.05; c p < 10-4